Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; ...

The US Food and Drug Administration (FDA) has accepted Novo Nordisk’s new drug application (NDA) submission for the 25 mg ...

Novo Nordisk has launched its hugely popular weight-loss drug Wegovy in Thailand, an executive of the Danish drugmaker's ...

Doctors have explained the potential pros and cons of these so-called 'skinny jabs', with everything from nausea to abdominal ...

Pharmaceutical company Novo Nordisk will expand its production site in Montes Claros, Brazil, creating 600 jobs.

Brazil, which hosts this year's United Nations climate summit, has a main goal of persuading Europe, China and other ...

Novo Nordisk (NYSE: NVO), the Danish drugmaker that's been riding high ever since it began putting out Ozempic and Wegovy GLP-1 injectables for treatment of diabetes and weight loss, got another ...

Novo Nordisk A/S (NYSE:NVO ... it announced an investment of just over one billion dollars in Brazil in a bid to boost the production of both Wegovy and Ozempic. Brazil is a major manufacturing ...

According to the alert, Novo Nordisk first notified the FDA about ... after being notified of counterfeit batches being sold in Brazil, the UK, and the U.S. Then as now, the FDA is warning people ...

Ironically, Ozempic and Wegovy, as with many of Novo Nordisk’s other products ... to invest billions to expand its production site in Brazil, and it recently saw some management changes.

Eli Lilly and Novo Nordisk dominate the billion-dollar weight loss drug market. Lilly has announced positive trial results from a candidate that could be a game changer in this area of high demand.